PCM
TMO icon

Prelude Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Prelude Capital Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-700
Closed -$319K – 1960
2021
Q1 		$319K Buy
+700
New +$334K 0.01% 1110
2019
Q2 		– Sell
-15,000
Closed -$4.11M – 2143
2019
Q1 		$4.11M Hold
15,000
– – 0.23% 73
2018
Q4 		$3.36M Buy
+15,000
New +$3.52M 0.22% 83

Other funds holding TMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Prelude Capital Management's TMO Position: Q1 2026 in Review

Prelude Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 50% in Q1 2026, selling an estimated $446K and leaving 836 shares worth $411K. The position accounts for 0.03% of the portfolio, ranked #587.

Prelude Capital Management first reported a position in TMO in Q2 2013 and has held it in 32 quarters since. The position peaked at $2.36M in Q1 2022. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Prelude Capital Management held 836 shares of Thermo Fisher Scientific worth $411K as of Q1 2026.
  • Prelude Capital Management sold 822 Thermo Fisher Scientific shares in Q1 2026, an estimated $446K.
  • Thermo Fisher Scientific made up 0.03% of Prelude Capital Management's portfolio in Q1 2026, its #587 holding.
  • Prelude Capital Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 32 quarters since.
  • Prelude Capital Management's Thermo Fisher Scientific position peaked at $2.36M in Q1 2022.
  • 2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.